Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) has made a 6.47% comeback from a 12-month low price of $7.42. It was seen 5.33% higher, changing the price to $7.9, when the closing bell rang on 3/14/2019. At a recent session, the prices were hovering between $7.43 and $7.95. This company shares are 264.3% off its target price of $28.78 and the current market capitalization stands at $219.94M. The recent change has given its price a -15.16% deficit over SMA 50 and -75.99% deficit over its 52-week high. The stock witnessed -13% declines, -17.28% declines and -64.94% declines for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found ADMS’s volatility during a week at 4.93% and during a month it has been found around 6.07%.
Adamas Pharmaceuticals, Inc. (ADMS) Top Holders
Institutional investors currently hold around $189 million or 0% in ADMS stock. Look at its top three institutional owners: Macquarie Group Ltd owns $20.31 million in Adamas Pharmaceuticals, Inc., which represents roughly 9.24% of the company’s market cap and approximately 10.75% of the institutional ownership. Similar statistics are true for the second largest owner, Broadfin Capital, Llc, which owns 2,614,468 shares of the stock are valued at $19.61 million. The third largest holder is Point72 Asset Management, L.P., which currently holds $19.25 million worth of this stock and that ownership represents nearly 8.75% of its market capitalization.
Adamas Pharmaceuticals, Inc. 13F Filings
At the end of December reporting period, 58 institutional holders increased their position in Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) by some 6,339,063 shares, 68 decreased positions by 6,633,867 and 14 held positions by 12,293,588. That puts total institutional holdings at 25,266,518 shares, according to SEC filings. The stock grabbed 16 new institutional investments totaling 1,453,787 shares while 41 institutional investors sold out their entire positions totaling 3,884,433 shares.
Adamas Pharmaceuticals, Inc. (ADMS) Analyst Guide
Several analysts have released their opinion on Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS), with 3 analysts believing it is a strong buy. Whereas 3 of them predict the stock is a hold. Also, there are 5 buy, 1 sell and 0 strong sell ratings, collectively assigning a 2.17 average brokerage recommendation [T1].